Collaboration Profit and Loss - Additional Information (Detail) - USD ($) $ in Thousands		3 Months Ended
		Mar. 31, 2024	Mar. 31, 2023	Dec. 31, 2023	Jul. 21, 2021	Jul. 01, 2021
Business Acquisition [Line Items]
Collaboration (profit)/loss related to pre-launch activities	[1]	$ 0	$ 3,607
Topic 808 [Member] | Nestle Health Science [Member] | 2021 License Agreement [Member]
Business Acquisition [Line Items]
Transaction price allocated under collaborative arrangement					$ 35,500	$ 35,500
Topic 808 [Member] | Total Liabilities [Member] | Nestle Health Science [Member] | 2021 License Agreement [Member]
Business Acquisition [Line Items]
Transaction price allocated under collaborative arrangement						$ 35,500
Topic 808 [Member] | Accrued Expenses and Other Current Liabilities [Member] | Nestle Health Science [Member] | 2021 License Agreement [Member]
Business Acquisition [Line Items]
Transaction price allocated under collaborative arrangement		10,064		$ 10,064
Research and Development Expenses [Member] | Topic 808 [Member] | Nestle Health Science [Member] | 2021 License Agreement [Member]
Business Acquisition [Line Items]
Cost associated with pre-launch activities		0	801
General and Administrative Expenses [Member] | Topic 808 [Member] | Nestle Health Science [Member] | 2021 License Agreement [Member]
Business Acquisition [Line Items]
Cost associated with pre-launch activities		$ 0	$ 2,703

[1] Includes non-cash collaboration profits and losses related to pre-launch activities; subsequent to the approval of VOWST in April 2023, collaboration (profit) loss sharing - related party is included within changes in operating assets and liabilities